KRAS variants in human pancreatic cancer: new key findings
Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.
List view / Grid view
Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
The model enables researchers to expand the number of tumours that they can study, increasing their ability to detect novel interactions.
This study is the first to demonstrate that NSD2 is foundational to the earliest stage of prostate cancer development.
The study’s findings could contribute to future therapeutic strategies to prevent chronic kidney disease.
Mice with rod-specific VPS35 deletion demonstrate a pathology more similar to human Parkinson’s disease, compared to other mouse models.
In this Q&A, Sheila Keating, Vice President of Immunology at GigaGen, a Grifols company, explains how its developments in recombinant polyclonal antibody therapies are helping to build a pipeline of highly effective treatments for a wide range of diseases, including the hepatitis B virus.
Researchers have developed a new in vitro co-culture system which enables an in-depth molecular analysis of atherosclerosis.
In this Q&A, Celularity’s CEO and founder Dr Robert Hariri details the preclinical research that indicates that placenta-derived unmodified NK cells and genetically modified NK cells can target and selectively eliminate cells expressing stress ligands.
The discovery that CNTN4 and APP have a co-dependent relationship has wider implications for neurodevelopmental disorder understanding.
Researchers identified variants in three loci that were associated with risk of triple-negative breast cancer.
Researchers uncover a genetic pathway of parietal cell development, which will enable a better understanding of stomach conditions.
Researchers have revealed that genetically enhanced expression of GSDMB causes a disturbed interferon-response.
The study’s findings explain the genetic differences in people’s blood pressure, which could lead to personalised medicine approaches.
Four previously unknown genetic variants provide a new understanding of differences in risk between individuals of varying ancestries.